Neutralization of the autophagy-repressive tissue hormone DBI/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) enhances anticancer immunosurveillance.

Léa Montégut, Isabelle Martins, Guido Kroemer

Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Inserm U1138, Université Paris Cité, Sorbonne Université, Paris, France.Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Inserm U1138, Université Paris Cité, Sorbonne Université, Paris, France. · pubmed

Paper

Abstract

The plasma concentration of the macroautophagy/autophagy inhibitor DBI/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) increases with aging and body mass index (BMI). Both advanced age and obesity are among the most important risk factors for the development of cancer. We observed that patients with cancer predisposition syndromes due to mutations in

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper discusses the role of the autophagy inhibitor DBI/ACBP in relation to aging and cancer, highlighting a potential mechanism that links obesity and advanced age to cancer risk. While it touches on factors associated with aging, the focus is primarily on cancer immunotherapy rather than addressing the root causes of aging or lifespan extension. Therefore, it presents solid research but with limited impact on the broader field of longevity.

Author of this paper? Send a correction.